Evidence map›Paper›PMID 24903149›Full record

ArticleCancer research2014

miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells.

Min Jin, Tao Zhang, Can Liu, Mark A Badeaux, Bigang Liu, Ruifang Liu, Collene Jeter, Xin Chen, Alexander V Vlassov, Dean G Tang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 134 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Min JinDepartment of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, Hubei; and.
Tao ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, Hubei; and.
Can LiuDepartment of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville;
Mark A BadeauxDepartment of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville;
Bigang LiuDepartment of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville;
Ruifang LiuDepartment of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville; Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Collene JeterDepartment of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville;
Xin ChenDepartment of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville;
Alexander V VlassovThermoFisher Scientific, Austin, Texas;
Dean G TangDepartment of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville; Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China dtang@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USHuazhong University of Science and Technology · CNShanghai East Hospital · CNThermo Fisher Scientific (United States) · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Decoding NanogP8 in TumorigenesisR01CA155693 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI TANG, DEAN G. · 2012 to 2016
$1.6M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA155693NCI NIH HHS R01-CA155693
6 · The paper itself

Abstract

microRNA-128 (miR128) is reduced in prostate cancer relative to normal/benign prostate tissues, but causal roles are obscure. Here we show that exogenously introduced miR128 suppresses tumor regeneration in multiple prostate cancer xenograft models. Cancer stem-like cell (CSC)-associated properties were blocked, including holoclone and sphere formation as well as clonogenic survival. Using a miR128 sensor to distinguish cells on the basis of miR128 expression, we found that miR128-lo cells possessed higher clonal, clonogenic, and tumorigenic activities than miR128-hi cells. miR128 targets the stem cell regulatory factors BMI-1, NANOG, and TGFBR1, the expression of which we found to vary inversely with miR128 expression in prostate cancer stem/progenitor cell populations. In particular, we defined BMI-1 as a direct and functionally relevant target of miR128 in prostate cancer cells, where these genes were reciprocally expressed and exhibited opposing biological functions. Our results define a tumor suppressor function for miR128 in prostate cancer by limiting CSC properties mediated by BMI-1 and other central stem cell regulators, with potential implications for prostate cancer gene therapy.

Indexed as

AnimalsCell Line, TumorGenetic TherapyHumansMaleMice, Inbred NODMice, SCIDMicroRNAsNeoplastic Stem CellsPolycomb Repressive Complex 1Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantTransfectionXenograft Model Antitumor AssaysBMI1 protein, humanMicroRNAsMIRN128 microRNA, humanPolycomb Repressive Complex 1

Identifiers

PMID24903149
PMCPMC4174451
OpenAlexW2021950951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.